News

Materials scientists have shown that it is possible to achieve photon up-conversion, – the emission of light with energy higher than the one that excites the material. This development brings scientists a step closer to developing minimally invasive photodynamic cancer treatments,

A newly published study shows that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells.

Recently, Urania Therapeutics announced that it has successfully raised €3.53M ($3.89M) in seed funding to unlock the therapeutic potential of ribosome-based treatments. We spoke with Jean-Paul Renaud, President and CSO of Urania Therapeutics, to learn more about the mechanisms of readthrough compounds and how the company hopes to provide treatment solutions for orphan diseases.

Long-term chronic treatment with opioids prior to trauma enhances fear learning in mice, according to a new study. These findings may suggest a potential mechanism underlying the frequent co-occurrence of post-traumatic stress disorder (PTSD) and opioid dependence.

New findings reveal that the three drugs, levetiracetam, fosphenytoin, and valproate, are equally safe and effective in treating patients with refractory status epilepticus.

A new has found that an orally administered liquid salt called Choline and Geranate or “CAGE” can physically reduce the absorption of fats from food with no obvious side effects in rats, and decreases total body weight by about 12% when a high-fat diet is consumed.

Pharmacist-led interventions such as patient education, medication review, and medication management can be pivotal in preventing heart-related illnesses suggests new study.

A new study outlines technique that will allow chemists to more closely control the size and shape of nanoparticles.

New pictures of a key mediator of drug resistance for the malaria parasite are now giving researchers clues about how to combat resistance.

Northwestern Engineering researchers have now developed a quick, cell-free system to build and study biosynthetic pathways. Called GlycoPRIME, the system could lead to faster development of therapeutics and a new, modular way to make medicines on demand in resource-limited settings.